Health
AstraZeneca’s Farxiga prolongs survival in chronic kidney disease trial – Clinical Trials Arena
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease…
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD).
The trial data showed that Farxiga helped reduce the composite of worsening of kidney function or risk of cardiovascular (CV) or renal death.
Farxiga is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used for treating patients with insufficiently controlled type-2 diabetes (T2D).
The international, multi-centre, randomised and…
-
General24 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
Noosa News9 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News23 hours agoPolice charge second man over alleged assault in Gold Coast car seller on Facebook’s Marketplace
-
General19 hours agoSharp rise in airfares push UK inflation higher in July